IPP Bureau
Medanta to set up a 400-bed super specialty hospital in Guwahati
By IPP Bureau - April 30, 2025
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
ekincare raises investment from MSD IDEA Studio Asia Pacific
By IPP Bureau - April 30, 2025
ekincare has raised a total funding of $22M since 2015 till date
Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr
By IPP Bureau - April 29, 2025
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
By IPP Bureau - April 29, 2025
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
IOL Chemicals and Pharmaceuticals receives approval CDE of NMPA, China for Ibuprofen
By IPP Bureau - April 29, 2025
This approval authorizes the company to export Ibuprofen to the Chinese markets
Closure of USFDA inspection at Zydus' API Unit at Dabhasa, Gujarat
By IPP Bureau - April 29, 2025
The inspection concluded with 6 observations and none of them were related to Data Integrity
Morepen to launch new fatty lever drug ‘Resmetirom’
By IPP Bureau - April 29, 2025
Thermo Fisher Scientific to invest $2 billion to expand US operation
By IPP Bureau - April 29, 2025
Investment demonstrates confidence in America’s commitment to science and innovation
Merck breaks ground on new $1 billion Biologics Center of Excellence in Delaware, US
By IPP Bureau - April 29, 2025
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
By IPP Bureau - April 29, 2025
Delivers robust earnings performance, successfully navigating a dynamic environment
Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
By IPP Bureau - April 28, 2025
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe
By IPP Bureau - April 28, 2025
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
By IPP Bureau - April 28, 2025
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Dr. Lal Path Labs posts Q4 FY25 consolidated PAT at Rs. 154.8 Cr
By IPP Bureau - April 28, 2025
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Zydus Lifesciences to acquire 85.6 % stake in Amplitude Surgical
By IPP Bureau - April 26, 2025
The closing of the Block Acquisition is now expected to be completed by Q3 2025
